Waters Q3 2026 Results: Net Income $81 Million on Revenue of $1.77 Billion
- US stocks
- Earnings
- Health Care

Waters (NYSE: WAT) reported GAAP revenue of $1.77 billion and GAAP net income of $81.0 million for the third quarter of 2026, which ended 3 Oct 2026, it said on 3 Nov 2026. GAAP diluted EPS was $0.82. The company's adjusted EPS, a company-defined measure that excludes items such as acquisition-related amortization and restructuring costs, was $4.10.
Key highlights
- Revenue (GAAP): $1.77 billion, up 120.9% YoY and 7.4% QoQ
- Net income (GAAP): $81.0 million, down 45.6% YoY
- Diluted EPS (GAAP): $0.82, down 67.2% YoY
- Adjusted EPS (company-defined): $4.10, up 21% YoY
- Full-year 2026 adjusted EPS guidance (company-defined): $14.60 to $14.70
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,767.0 | 800.0 | +120.9% | 1,645.0 | +7.4% |
| 128.0 | 192.0 | -33.3% | -86.0 | n/a | |
| Operating margin | 7.24% | 24.00% | -16.76 pp | -5.23% | +12.47 pp |
| 81.0 | 149.0 | -45.6% | -136.0 | n/a | |
| Net income margin | 4.58% | 18.62% | -14.04 pp | -8.27% | +12.85 pp |
| Diluted EPS ($) | 0.82 | 2.50 | -67.2% | -1.39 | n/a |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 3 Oct 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table compares GAAP revenue of $1.77 billion with $800.0 million a year earlier, a rise of 120.9%. The release splits the quarter's revenue into $871 million of organic revenue and $896 million from the acquired Biosciences and Diagnostic Solutions (BDS) businesses.
GAAP operating margin was 7.2%, against 24.0% a year earlier, a fall of 16.8 percentage points. Net income was 4.6% of revenue, against 18.6% a year earlier. Operating income was $128.0 million, against a loss of $86.0 million in the previous quarter.
Adjusted figures exclude acquisition and restructuring items
The company's adjusted operating income was $532 million, a 30.1% adjusted operating margin, and adjusted net income was $404 million. The company calls these non-GAAP measures and says they exclude items such as purchased intangibles amortization, acquisition-related fair value step-ups, restructuring costs and acquisition-related costs.
Operating cash flow was $98.0 million, against $187.0 million a year earlier. Adjusted free cash flow, the company's own measure, was $68 million against $160 million. The company said net receivables due from the BDS acquisition TSA provider rose by $17 million in the quarter.
Organic revenue grew 9% as reported
Organic revenue was $871 million, up 9% as reported and 10% in constant currency. The company describes organic constant currency growth as a non-GAAP measure that excludes currency effects and acquisitions made within the previous twelve months.
On a GAAP basis, the Analytical Sciences Division reported $703.0 million against $649.0 million a year earlier. The Biosciences Division reported $396.0 million, against $387.0 million for the prior-year comparable period. The Advanced Diagnostics Division reported $575.0 million, of which Diagnostic Solutions was $500.0 million and the Clinical Business Unit $75.0 million. The Materials Sciences Division reported $93.0 million, against $87.0 million.
The company said LC-MS instrument sales grew double digits in constant currency, and that reagents in the Biosciences Division grew high single digits on a prior-year comparable basis.
Full-year 2026 guidance raised
The company now expects full-year 2026 total reported revenue of $6.479 billion to $6.497 billion and adjusted EPS of $14.60 to $14.70. The release prints no earlier ranges for these lines. It says the company is lifting every line of its full-year outlook, with reported revenue up $43 million at the midpoint.
For the fourth quarter, the company expects reported revenue of $1.801 billion to $1.819 billion and adjusted EPS of $4.58 to $4.68. The company also said it has acquired MOBILion Systems, Inc., which it describes as a pioneer of SLIM high-resolution ion mobility separation technology.
Inference
Weighted-average diluted shares were 98,653 in the quarter, against 59,622 a year earlier, as the statement of operations prints them. Purchases of treasury shares were $1 million, and the release mentions no dividend.
The release does not give the price or terms of the MOBILion acquisition. The next dated step in the release is the end of the fourth quarter guidance period on 31 Dec 2026.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

